jeudi 14 septembre 2017

Onco Actu du 14 septembre 2017

1. Biologie

Mutational Signature Analysis Reveals Breast Cancers With Mismatch Repair Deficiencies [AACR]

3.1 Prévention - Tabac

Tobacco company launches foundation to stub out smoking [The Guardian]

3.3 Prévention - Vaccins

What's Next after Creating a Cancer-Prevention Vaccine? [Scientific American]

5. Traitements

FDA-approved drug may block resistance to anti-angiogenesis therapy [Mass. General Hospital]

5.10 Traitements - Essais

Clinical trial matching platform raises $11M backed by Merck’s tech fund [FierceBiotech]

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer [Astellas]

5.12 Immunothérapies

Can the culprit for cancer spreading also boost immuno-oncology treatments? [FierceBiotech]

5.12.1 Immunothérapies - partenariats

Seeking an edge in a fiercely-fought field, Bristol-Myers pays Halozyme $105M to access I-O delivery tech [FierceBiotech]

Halozyme Inks $105M Bristol-Myers Partnership, Expands Roche Deal [Xconomy]

Looking for an I/O edge, Bristol-Myers fronts $105M to partner with Halozyme as Roche expands pact [EndPoints]

5.2 Pharma

Hemo-oncology newbie Bayer gears up for copanlisib launch [FiercePharma]

5.4 Traitements - Economie

Drug Companies Tie Costs to Outcomes [Wall Street Journal]

5.9 AACR

AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives [Cancer Research Catalyst]

6.1 Observation

Childhood cancer survivors face lifetime of chronic health conditions [Reuters]

6.11 Patients

Cancer patients know immuno-oncology and top drugs, but lack details: study [FiercePharma]

6.6 Publications

Making Peer Review More Transparent with Open Annotation [ORCID]

6.8 Communication

Worrisome ‘right to try’ legislation may soon become law. Here’s the story that some news outlets missed [HealthNewsReview]

6.9 Controverses

STAT becomes 3rd major organization to revise policies after our scrutiny [HealthNewsReview]

This $25,000 Life-Extension Test Is Impressing Investors But Not Doctors [Bloomberg]